Skye Bioscience, Inc.
Case Overview
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 01/16/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Skye Bioscience, Inc. |
| Court: | Court: Southern District of California |
| Case Number: | Case Number: 3:25cv03177 |
| Class Period: | Class Period: 11/04/2024 - 10/03/2025 |
| Ticker: | Ticker: SKYE |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Skye's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) nimacimab was less effective than Defendants had led investors to believe; (ii) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times. On October 6, 2025, Skye issued a press release "announcing the topline data from its 26-week Phase 2a CBeyond proof-of-concept study of nimacimab[.]" The press release disclosed that the "the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo" and that "preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy." On this news, Skye's stock price fell $2.85 per share, or 60%, to close at $1.90 per share on October 6, 2025.